120 related articles for article (PubMed ID: 3910864)
21. Lineage differentiation of canine lymphoma/leukemias and aberrant expression of CD molecules.
Wilkerson MJ; Dolce K; Koopman T; Shuman W; Chun R; Garrett L; Barber L; Avery A
Vet Immunol Immunopathol; 2005 Jul; 106(3-4):179-96. PubMed ID: 15963817
[TBL] [Abstract][Full Text] [Related]
22. [Flow cytometric analysis of malignant cells in lymphocytic leukemias and lymphomas by monoclonal antibodies].
Imamura N; Kuramoto A
Rinsho Ketsueki; 1988 Aug; 29(8):1227-36. PubMed ID: 3264587
[No Abstract] [Full Text] [Related]
23. Monoclonal antibody studies in B(non-T)-cell malignancies.
Shimoyama M; Minato K; Tobinai K; Nagai M; Hirose M
Jpn J Clin Oncol; 1983 Sep; 13(3):477-88. PubMed ID: 6417373
[TBL] [Abstract][Full Text] [Related]
24. Immunohistochemical typing of non-Hodgkin's lymphoma-comparing working formulation and WHO classification.
Kalyan K; Basu D; Soundararaghavan J
Indian J Pathol Microbiol; 2006 Apr; 49(2):203-7. PubMed ID: 16933715
[TBL] [Abstract][Full Text] [Related]
25. [Pathology of Hodgkin's lymphoma].
Hansmann ML; Willenbrock K
Verh Dtsch Ges Pathol; 2003; 87():53-7. PubMed ID: 16888894
[TBL] [Abstract][Full Text] [Related]
26. [Classification and morphology of non-Hodgkin's lymphomas].
Lennert K
Hamatol Bluttransfus; 1976; 18():145-50. PubMed ID: 1085714
[No Abstract] [Full Text] [Related]
27. Reduced natural killer cell activity in non-hodgkin's lymphoma.
Neri A; Brugiatelli M; Ozger Topuz U; Astaldi G
Boll Ist Sieroter Milan; 1981 Nov; 60(5):394-407. PubMed ID: 7041921
[TBL] [Abstract][Full Text] [Related]
28. The clinical relevance of lymphocyte surface markers in leukemia and lymphoma.
Bloomfield CD; Gajl-Peczalska KJ
Curr Top Hematol; 1980; 3():175-240. PubMed ID: 6276102
[No Abstract] [Full Text] [Related]
29. [The evaluation of peripheral blood lymphoid cells in children in remission a year after the cessation of treatment for acute lymphoblastic leukemia and non-Hodgkin's lymphoma type non-B].
Wylezoł I; Mazur B; Sońta-Jakimczyk D; Olejnik I
Wiad Lek; 1998; 51 Suppl 4():140-4. PubMed ID: 10731958
[TBL] [Abstract][Full Text] [Related]
30. How to differentiate between T-cell-rich B-cell lymphoma and lymphocyte-predominant Hodgkin's disease. Evidence for the value of MB1 and 4KB5 immunostaining.
Schmidt U; Herbst J; Metz KA; Leder LD
J Pathol; 1996 Jun; 179(2):138-44. PubMed ID: 8758204
[TBL] [Abstract][Full Text] [Related]
31. Use of monoclonal antibodies, morphology, and cytochemistry to probe the cellular heterogeneity of acute leukemia and lymphoma.
LeBien TW; McKenna RW; Abramson CS; Gajl-Peczalska KJ; Nesbit ME; Coccia PF; Bloomfield CD; Brunning RD; Kersey JH
Cancer Res; 1981 Nov; 41(11 Pt 2):4776-80. PubMed ID: 6945905
[TBL] [Abstract][Full Text] [Related]
32. The pathology of non-Hodgkin's lymphoma.
Kay S
Prog Clin Biol Res; 1978; 25():1-5. PubMed ID: 310556
[No Abstract] [Full Text] [Related]
33. Preparation and characterization of monoclonal antibodies recognizing three distinct differentiation antigens (BL1, BL2, BL3) on human B lymphocytes.
Wang CY; Azzo W; Al-Katib A; Chiorazzi N; Knowles DM
J Immunol; 1984 Aug; 133(2):684-91. PubMed ID: 6429242
[TBL] [Abstract][Full Text] [Related]
34. [Malignant lymphoma-related disorder with a severe prognosis and anomalous surface phenotype (OKT10+, T11+, NKH-1+)].
Abe K; Imamura N; Kuramoto A; Yokozaki H
Rinsho Ketsueki; 1988 Feb; 29(2):203-7. PubMed ID: 3260296
[No Abstract] [Full Text] [Related]
35. Immunohistochemical analysis of the distribution of lymphocyte subpopulations in Hodgkin's disease.
Borowitz MJ; Croker BP; Metzgar RS
Cancer Treat Rep; 1982 Apr; 66(4):667-74. PubMed ID: 6210433
[TBL] [Abstract][Full Text] [Related]
36. B lymphocytes in untreated patients with malignant lymphoma and Hodgkin's disease.
Gajl-Peczalska KJ; Hansen JA; Bloomfield CD; Good RA
J Clin Invest; 1973 Dec; 52(12):3064-73. PubMed ID: 4201499
[TBL] [Abstract][Full Text] [Related]
37. IL-2Ralpha-Directed monoclonal antibodies provide effective therapy in a murine model of adult T-cell leukemia by a mechanism other than blockade of IL-2/IL-2Ralpha interaction.
Phillips KE; Herring B; Wilson LA; Rickford MS; Zhang M; Goldman CK; Tso JY; Waldmann TA
Cancer Res; 2000 Dec; 60(24):6977-84. PubMed ID: 11156399
[TBL] [Abstract][Full Text] [Related]
38. B-cell malignancies and differentiation antigens defined with monoclonal antibodies.
Kikuchi K; Koshiba H; Kasai K; Hiratsuka H; Fujimoto N; Uede T
Jpn J Clin Oncol; 1983 Sep; 13(3):517-31. PubMed ID: 6417375
[TBL] [Abstract][Full Text] [Related]
39. Antibody probes in diagnosis and classification of lymphomas.
Jones EL
J Pathol; 1983 Nov; 141(3):259-86. PubMed ID: 6363648
[TBL] [Abstract][Full Text] [Related]
40. Fas ligand expression in nodal non-Hodgkin's lymphoma.
Müllauer L; Mosberger I; Chott A
Mod Pathol; 1998 Apr; 11(4):369-75. PubMed ID: 9578088
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
